481 related articles for article (PubMed ID: 25006133)
21. IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells.
Mao Y; van Hoef V; Zhang X; Wennerberg E; Lorent J; Witt K; Masvidal L; Liang S; Murray S; Larsson O; Kiessling R; Lundqvist A
Blood; 2016 Sep; 128(11):1475-89. PubMed ID: 27465917
[TBL] [Abstract][Full Text] [Related]
22. Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rg(null) mice.
Cany J; van der Waart AB; Tordoir M; Franssen GM; Hangalapura BN; de Vries J; Boerman O; Schaap N; van der Voort R; Spanholtz J; Dolstra H
PLoS One; 2013; 8(6):e64384. PubMed ID: 23755121
[TBL] [Abstract][Full Text] [Related]
23. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
Liu E; Tong Y; Dotti G; Shaim H; Savoldo B; Mukherjee M; Orange J; Wan X; Lu X; Reynolds A; Gagea M; Banerjee P; Cai R; Bdaiwi MH; Basar R; Muftuoglu M; Li L; Marin D; Wierda W; Keating M; Champlin R; Shpall E; Rezvani K
Leukemia; 2018 Feb; 32(2):520-531. PubMed ID: 28725044
[TBL] [Abstract][Full Text] [Related]
24. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells.
Leong JW; Chase JM; Romee R; Schneider SE; Sullivan RP; Cooper MA; Fehniger TA
Biol Blood Marrow Transplant; 2014 Apr; 20(4):463-73. PubMed ID: 24434782
[TBL] [Abstract][Full Text] [Related]
25. Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model.
Geller MA; Knorr DA; Hermanson DA; Pribyl L; Bendzick L; McCullar V; Miller JS; Kaufman DS
Cytotherapy; 2013 Oct; 15(10):1297-306. PubMed ID: 23993303
[TBL] [Abstract][Full Text] [Related]
26. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo.
Lakshmikanth T; Burke S; Ali TH; Kimpfler S; Ursini F; Ruggeri L; Capanni M; Umansky V; Paschen A; Sucker A; Pende D; Groh V; Biassoni R; Höglund P; Kato M; Shibuya K; Schadendorf D; Anichini A; Ferrone S; Velardi A; Kärre K; Shibuya A; Carbone E; Colucci F
J Clin Invest; 2009 May; 119(5):1251-63. PubMed ID: 19349689
[TBL] [Abstract][Full Text] [Related]
27. An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma.
Ma R; Lu T; Li Z; Teng KY; Mansour AG; Yu M; Tian L; Xu B; Ma S; Zhang J; Barr T; Peng Y; Caligiuri MA; Yu J
Cancer Res; 2021 Jul; 81(13):3635-3648. PubMed ID: 34006525
[TBL] [Abstract][Full Text] [Related]
28. Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.
Liu Y; Wu HW; Sheard MA; Sposto R; Somanchi SS; Cooper LJ; Lee DA; Seeger RC
Clin Cancer Res; 2013 Apr; 19(8):2132-43. PubMed ID: 23378384
[TBL] [Abstract][Full Text] [Related]
29. Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells.
Zhang H; Cui Y; Voong N; Sabatino M; Stroncek DF; Morisot S; Civin CI; Wayne AS; Levine BL; Mackall CL
J Immunother; 2011 Mar; 34(2):187-95. PubMed ID: 21304401
[TBL] [Abstract][Full Text] [Related]
30. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
31. Implication of Highly Cytotoxic Natural Killer Cells for Esophageal Squamous Cell Carcinoma Treatment.
Lim KS; Mimura K; Kua LF; Shiraishi K; Kono K
J Immunother; 2018; 41(6):261-273. PubMed ID: 29683892
[TBL] [Abstract][Full Text] [Related]
32. Immunodeficient mouse strains display marked variability in growth of human melanoma lung metastases.
Carreno BM; Garbow JR; Kolar GR; Jackson EN; Engelbach JA; Becker-Hapak M; Carayannopoulos LN; Piwnica-Worms D; Linette GP
Clin Cancer Res; 2009 May; 15(10):3277-86. PubMed ID: 19447870
[TBL] [Abstract][Full Text] [Related]
33. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo.
Nagashima S; Mailliard R; Kashii Y; Reichert TE; Herberman RB; Robbins P; Whiteside TL
Blood; 1998 May; 91(10):3850-61. PubMed ID: 9573023
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of tumor growth by NK1.1+ cells and CD8+ T cells activated by IL-15 through receptor beta/common gamma signaling in trans.
Rowley J; Monie A; Hung CF; Wu TC
J Immunol; 2008 Dec; 181(12):8237-47. PubMed ID: 19050240
[TBL] [Abstract][Full Text] [Related]
35. Endogenous IL-2 production by natural killer cells maintains cytotoxic and proliferative capacity following retroviral-mediated gene transfer.
Miller JS; Tessmer-Tuck J; Blake N; Lund J; Scott A; Blazar BR; Orchard PJ
Exp Hematol; 1997 Oct; 25(11):1140-8. PubMed ID: 9328450
[TBL] [Abstract][Full Text] [Related]
36. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2
Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307
[TBL] [Abstract][Full Text] [Related]
37. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
Oelsner S; Waldmann A; Billmeier A; Röder J; Lindner A; Ullrich E; Marschalek R; Dotti G; Jung G; Große-Hovest L; Oberoi P; Bader P; Wels WS
Int J Cancer; 2019 Oct; 145(7):1935-1945. PubMed ID: 30860598
[TBL] [Abstract][Full Text] [Related]
38. Preclinical Evaluation of Off-The-Shelf PD-L1+ Human Natural Killer Cells Secreting IL15 to Treat Non-Small Cell Lung Cancer.
Lu T; Ma R; Mansour AG; Bustillos C; Li Z; Li Z; Ma S; Teng KY; Chen H; Zhang J; Villalona-Calero MA; Caligiuri MA; Yu J
Cancer Immunol Res; 2024 Jun; 12(6):731-743. PubMed ID: 38572955
[TBL] [Abstract][Full Text] [Related]
39. Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager.
Felices M; Lenvik TR; Kodal B; Lenvik AJ; Hinderlie P; Bendzick LE; Schirm DK; Kaminski MF; McElmurry RT; Geller MA; Eckfeldt CE; Vallera DA; Miller JS
Cancer Immunol Res; 2020 Sep; 8(9):1139-1149. PubMed ID: 32661096
[TBL] [Abstract][Full Text] [Related]
40. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
